BTK inhibitors

Jaypirca
Pharma

Lilly touts Jaypirca fixed-duration win in ‘ambitious’ CLL trial

In an industry first, Lilly found that adding Jaypirca to a fixed-duration regimen of venetoclax and rituximab significantly extended PFS.
Angus Liu Apr 13, 2026 10:16am
FDA approved stamp regulations yes go

AZ nabs Calquence fixed-duration nod to counter BeOne’s CLL push

Feb 20, 2026 11:05am
NVS

Novartis jockeys for Rhapsido FDA nod in unclaimed hives subtype

Feb 18, 2026 9:49am
Narasimhan

Novartis CEO eyes 2026 growth despite record patent cliff

Feb 4, 2026 2:30pm
Graham

Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop

Jan 29, 2026 11:23am
An envelope with rejected mark Vector illustration
Favicon Fierce Biotech

FDA shares CRL for Sanofi MS drug mere weeks after rebuff

Jan 6, 2026 4:30am